Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

98 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Both artemether-lumefantrine and chloroquine are currently used and recommended by Malaysian Ministry of Health as blood stage treatments for non-severe P. vivax and P. knowlesi malaria. Microscopic misdiagnosis between Plasmodium species remains a large issue in Sabah, Malaysia and elsewhere. In order to facilitate potential policy change to a unified ACT guideline for all malaria species in Sabah artemether-lumefantrine needs to be evaluated for P. vivax malaria.

Preliminary data in a recently completed RCT evaluating artesunate-mefloquine vs chloroquine for P. vivax showed up to 36% P. vivax recurrence with chloroquine monotherapy by day 28 post treatment without primaquine. Based on these data blood stage chloroquine treatment failure rates should also be evaluated in the context of standard concurrent (rather than delayed) liver stage primaquine dosing, due to both its potential blood stage synergistic effect in addition to known decreased recurrence rates. As artemether-lumefantrine is one of the current first line Ministry of Health ACTs used in Sabah with a lower adverse event profile compared to artesunate-mefloquine, this was recommended as the more appropriate ACT to evaluate against chloroquine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014

NCT04222088

Malaria Falciparum Malaria Vivax Malaria +1 more

COMPLETED

P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine

NCT02001012

Uncomplicated Knowlesi Malaria

COMPLETED PHASE3

P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine

NCT01708876

Uncomplicated Plasmodium Knowlesi Malaria

COMPLETED PHASE3

Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines

NCT00229775

Malaria

COMPLETED NA

In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria

NCT02637128

MALARIA, FALCIPARUM

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Malaria due to infection with P. vivax is currently estimated at up to 390 million episodes per year worldwide, with substantial morbidity caused by the recurrent nature of its infection, associated anaemia and adverse effects on pregnancy, and ability to cause severe disease and death. The majority of malaria cases from all Plasmodium species in Malaysia are from the Eastern state of Sabah, where despite around a 36-fold reduction in incidence since the implementation of malaria eradication programs in 1961, minimum estimates based on unpublished microscopy data from Sabah State public health records still detailed 8685 malaria cases in 2009-2011. While P. vivax accounts for between 30-50% of these figures currently, studies have demonstrated as overall transmission rates in countries previously endemic for malaria decline the proportion of cases attributable to P. vivax increases. Mixed P. falciparum / P. vivax infections are also likely to be underestimated in areas of co-endemicity, with high rates of recurrence of P. vivax shown in studies following treatment for apparent P. falciparum mono-infection or mixed Plasmodium spp. infections.

Malaysian Ministry of Health guidelines currently recommends chloroquine and primaquine as first line treatment for the erythrocytic and hypnozoite life stages of uncomplicated P. vivax malaria respectively. While resistance to chloroquine has previously been documented in Sabah and also Peninsular Malaysia, the unstable transmission dynamics and recent reduction in P. vivax incidence due to public health measures mean the current risk of chloroquine-resistant P.vivax transmission is likely to be low. Despite this, due to documented increasing resistance in surrounding countries including Indonesia, Thailand, Vietnam, and PNG, transient populations of migrant workers, and recent concerns of the failing efficacy of hypnozoite eradication by primaquine, the need for ongoing therapeutic efficacy monitoring is recommended.

There is also growing support for artemisinin-based combination therapy (ACT) as a unified first line treatment choice in areas co-endemic for P. falciparum and P. vivax, as adopted by a small number of countries including PNG, Solomon Islands, Vanuatu and Papua, Indonesia, due to the regional increase of chloroquine-resistant P. vivax, and ongoing concerns over the microscopic misdiagnosis of Plasmodium species. This is also particularly relevant for P. knowlesi malaria, as it is frequently misidentified on microscopy as P. falciparum and P. malariae due to morphological similarities in the early trophozoite, and late trophozoite and schizont life stages respectively, with studies showing up to 80% of P. malariae and 7-12% of P. falciparum in this region are actually P. knowlesi when definitively evaluated with PCR. Misdiagnosis has concerning treatment implications, as although P. knowlesi has been shown to respond well to ACT and chloroquine, unlike P. malariae, knowlesi malaria has a rapid 24-hour replication rate and can cause hyperparasitaemia, severe complications and fatal outcomes, while the inadvertent use of chloroquine for widely chloroquine-resistant P. falciparum may also have fatal consequences.

Previous reluctance to use ACTs in presumed chloroquine-sensitive P.vivax areas were centered on concerns over efficacy and cost. The advent of generically produced ACTs is improving cost-related issues, while a recent Cochrane review of clinical trials looking at the use of ACT versus chloroquine for uncomplicated vivax malaria showed that ACTs are equivalent to chloroquine in preventing recurrent parasitaemia in the first 28 days (RR 1, 95% CI 0.30 to 3.39), and those with long half lives such as mefloquine or piperaquine are superior over a 6-8 week follow up, with fewer recurrent episodes after day 28 (RR 0.47, 95% CI 0.29 to 0.76). This post treatment prophylaxis benefit of longer acting agents extends to the reduction in gametocyte carriage, delay in relapse or re-infection and decreased risk of anaemia development, all of which contribute to decreased transmissibility and health care cost.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plasmodium Vivax Malaria Without Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Artemether-lumefantrine + Primaquine

1 tablet = 20mg artemether and 120mg lumefantrine. Dosing at 0, 8, 24, 36, 48 and 60 hours. Dose according to bodyweight; \>35kg = 2 tablets, 26-35kg = 3 tablets, 16-25kg = 2 tablets, \>10-15kg = 1 tablet.

Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; \>35kg = 30mg, \<35kg = 0.5mg/kg

Group Type ACTIVE_COMPARATOR

Artemether-lumefantrine + Primaquine

Intervention Type DRUG

Chloroquine + Primaquine

1 tablet contains 155mg chloroquine base. Adult dose (\>35kg); 620mg (4 tablets) at 0 hours, and 310mg (2 tablets) at 6-8, 24 and 48 hours.

Child dose (\>10-35kg); 10mg/kg at 0 hours, and 5mg/kg at 6-8, 24 and 48 hours. Primaquine = 7.5mg tablet. Dosing daily for 14 days from Day 0. Dose according to bodyweight; \>35kg = 30mg, 10-35kg = 0.5mg/kg

Group Type ACTIVE_COMPARATOR

Chloroquine + Primaquine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Artemether-lumefantrine + Primaquine

Intervention Type DRUG

Chloroquine + Primaquine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients at least 1 year of age and weighing more than 10kg
* Microscopic diagnosis of P. vivax monoinfection
* Negative P. falciparum malaria rapid diagnostic test (histidine-rich-protein 2)
* Fever (temperature ≥37.5°C) or history of fever in the last 48 hours
* Written informed consent to participate in trial

Exclusion Criteria

* Clinical or laboratory criteria for severe malaria, including warning signs, according to modified WHO 2010 criteria
* Parasitaemia \> 100,000 /μL
* Pregnancy or lactation
* Known hypersensitivity or allergy to study drugs
* Serious underlying disease (cardiac, renal or hepatic)
* Received anti-malarials in previous 2 months
* History of psychiatric illness, epilepsy, or cerebral malaria

Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No